Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Celmods potently inhibit m-MDSC induction by targeting IL-10 and MIF in multiple myeloma

Yui Niiyama-Uchibori, Yu Inoue, Shotaro Chinen et al. Nov 03, 2025 pp. 7447-7447 10.1182/blood-2025-7447

Abstract Background Myeloid-derived suppressor cells (MDSCs), which include polymorphonuclear-MDSCs and monocytic MDSCs (M-MDSCs), play key...

Impact of thrombocytopenia on hemorrhage and recurrent thrombosis in patients with cancer associated thrombosis, a time varying analysis

Vasiliki Xirou, Andrew Bueno, Joseph Thomas et al. Nov 03, 2025 pp. 1347-1347 10.1182/blood-2025-1347

Abstract IntroductionBoth venous thromboembolism (VTE) and thrombocytopenia are frequent complications in patients with cancer. Managing can...

MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study

Gang An, Wenming Chen, Wen Gao et al. Nov 03, 2025 pp. 2274-2274 10.1182/blood-2025-2274

Abstract Background: Multiple myeloma (MM) is a highly heterogeneous, incurable hematologic malignancy. BCMA and GPRC5D are highly expressed...

Rising mortality from coexisting hypertension and aplastic anemia in the United States, 1999–2023: A 25-year analysis of national disparities and public health gaps

Laiba Sultan, Swapna Gangasani, Nayanika Tummala et al. Nov 03, 2025 pp. 6454-6454 10.1182/blood-2025-6454

Abstract Background Hypertension is one of the most prevalent chronic conditions in the United States and a leading cont...

Functional analysis of STAT3 activating mutations in LGL leukemia reveals epigenetic reprograming and therapeutic vulnerabilities.

Zachary Hutchins, Robyn Keller, Molly Halloran et al. Nov 03, 2025 pp. 5035-5035 10.1182/blood-2025-5035

Abstract STAT3 activating mutations, present in 40-70% of large granular lymphocytic leukemia (LGLL) patients, are associated with worse pro...

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

William Johnson, Joseph Rocco, Rikita Patel et al. Nov 03, 2025 pp. 2996-2996 10.1182/blood-2025-2996

Abstract INTRODUCTION Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory state triggered by diverse conditions...

Automatic identification of blast leukemic cells types using deep learning with vision transformers.

Adriana Bornacelly, Jhon Sprockel, Maria Solano et al. Nov 03, 2025 pp. 2582-2582 10.1182/blood-2025-2582

Abstract Background: Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)are heterogeneous hematopoietic neoplasms with poor...

Establishing the impact of effective donor-specific antibody (DSA) desensitisation in haploidentical and mismatched donor haematopoietic stem cell transplants: An Australian experience

Louis Do, Elizabeth O'Flaherty, Claire Dowsing et al. Nov 03, 2025 pp. 4199-4199 10.1182/blood-2025-4199

Abstract Background: The presence of donor-specific antibodies (DSA) in recipients undergoing allogeneic hematopoietic stem cell transplant...

Chest imaging prior to allogeneic bone marrow transplant: A retrospective study of pre-transplant workup outcomes

Zoe Gunthert, Medha Guduru, Mohammad Mian et al. Nov 03, 2025 pp. 6215-6215 10.1182/blood-2025-6215

Abstract Introduction: Allogeneic bone marrow transplant (BMT) patients are prone to pulmonary infections and neutropenic fever due to their...

Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL

Mengyang Di, Xiaoliang Wang, Qianhong Fu et al. Nov 03, 2025 pp. 6283-6283 10.1182/blood-2025-6283

Abstract Background The chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treatment (tx) landscape has changed recently. The...

Caplacizumab for pediatric immune thrombotic thrombocytopenic purpura: A scoping review of current evidence

Abdulrahman Al-Mashdali, Samah M Salihb, Priyadarshini Vatsyayanc et al. Nov 03, 2025 pp. 1326-1326 10.1182/blood-2025-1326

Abstract Introduction: Immune thrombotic thrombocytopenic purpura (iTTP) in children is a rare form of thrombotic microangiopathy characteri...

Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher

Caitlin Rausch, Hagop Kantarjian, Nitin Jain et al. Nov 03, 2025 pp. 1575-1575 10.1182/blood-2025-1575

Abstract Background: Measurable residual disease (MRD) is the strongest predictor for relapse and survival in patients (pts) with B-cell acu...

Improving bone marrow biopsy core length and aspirate adequacy through implementation of a powered device: A single-institution quality improvement initiative

Chidambaram Ramasamy, Andrea Moran, Dong Chen et al. Nov 03, 2025 pp. 6176-6176 10.1182/blood-2025-6176

Abstract Background: Adequate bone marrow (BM) examination is essential for diagnosing, staging, and monitoring hematologic disorders. Subop...

Transitioning patients from warfarin to direct oral anticoagulants: A dual-benefit quality improvement initiative

Divya Viswanathan, Abiram Sivanandam, Joshua Kra et al. Nov 03, 2025 pp. 7897-7897 10.1182/blood-2025-7897

Abstract Background: Anticoagulation is commonly used to prevent and treat thromboembolic events. Warfarin is a cost-effective anticoagulant...

Cutaneous diffuse large B-cell lymphoma induce a macrophage immunosuppressive phenotype through IL-10 secretion

Rémi Peanne, Jean Galtier, Valerie Le Morvan et al. Nov 03, 2025 pp. 5031-5031 10.1182/blood-2025-5031

Abstract Background : Tumor associated macrophages (TAM) may endorse a large range of phenotype and functions owing to their plasticity and...

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Marta Lasa, Esperanza Martin-Sanchez, Aintzane Zabaleta et al. Nov 03, 2025 pp. 578-578 10.1182/blood-2025-578

Abstract Background: MGUS is considered a benign condition despite being associated with shorter survival when compared to matched control p...

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

David Coffey, Mark Meerson, Mainak Bardhan et al. Nov 03, 2025 pp. 7479-7479 10.1182/blood-2025-7479

Abstract Background: Several genomic research efforts in multiple myeloma (MM) have revealed clinically relevant molecular subgroups beyond...

Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients

Jing Pan, Siyu Liu, Ang Zhang et al. Nov 03, 2025 pp. 2370-2370 10.1182/blood-2025-2370

Abstract Background:Anti-CD19 CAR-T cell therapy has achieved breakthrough efficacy in B cell-driven autoimmune diseases such as systemic lu...

DDX3X facilitates adaption to proteotoxic stress by regulating the translation of MAPKAPK2 and the stability of TMCO1 via stress granules in multiple myeloma

Fengjuan Fan, Shijun Jiang, Enqi Ni et al. Nov 03, 2025 pp. 3944-3944 10.1182/blood-2025-3944

Abstract INTRODUCTION Endoplasmic reticulum stress (ERS) / unfolded protein response (UPR) is essential for multiple myeloma (MM) cell surviv...

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

Swetha Thiruvengadam, Lu Chen, Vi Lam et al. Nov 03, 2025 pp. 5373-5373 10.1182/blood-2025-5373

Abstract Background Bispecific antibodies offer chemotherapy-free, time-limited options with reduced toxicity and durable responses for fron...

The chromatin remodeling protein ARID1A is required for MLL-AF9 leukemogenesis

Kira Cozzolino, Mingguang Xue, Binyam Yilma et al. Nov 03, 2025 pp. 1465-1465 10.1182/blood-2025-1465

Abstract The SWI/SNF chromatin remodeling complexes regulate gene transcription by modulating chromatin accessibility. Three SWI/SNF subcomp...

A Canadian national needs assessment for an immunology curriculum for hematology residents

Jennifer Teichman, Eric Tseng, Christopher Lemieux et al. Nov 03, 2025 pp. 2867-2867 10.1182/blood-2025-2867

Abstract Background: Hematology training in Canada is competency-based and consists of two years of integrated clinical and laboratory train...

Genetics of lymphomas in Ecuador

Paola E. Leone, María Eugenia Sánchez, Melissa Arévalo et al. Nov 03, 2025 pp. 7054-7054 10.1182/blood-2025-7054

Abstract Lymphomas arise in any body region containing lymphatic tissue and are mainly classified into Hodgkin lymphoma (HL) and non-Hodgkin...

Hi-c FFPE sequencing analysis is highly concordant with FISH and detects additional variants informing diagnosis and treatment in diffuse large B-cell lymphoma

Zijun Xu-Monette, Dehong Wu, Chang Wang et al. Nov 03, 2025 pp. 3529-3529 10.1182/blood-2025-3529

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for approximatel...

Associations between chronic kidney disease, proteinuria, and thrombotic risk in SCD

Mary Sehl, Qin Sun, Nicole Herrera et al. Nov 03, 2025 pp. 1184-1184 10.1182/blood-2025-1184

Abstract Background: Sickle cell disease (SCD) is characterized by early onset of frailty and age-related complications, including heart dis...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page